AstraZeneca Financial Results: Strong Revenue Growth and Pipeline Expansion in FY 2025

By João L. Carapinha

February 11, 2026

AstraZeneca’s financial results for FY and Q4 2025 showcased total revenue of $58.7 billion, up 8% at constant exchange rates (CER) from FY 2024, driven by oncology leadership and pipeline momentum.

Oncology Fuels Revenue Surge

Oncology contributed 44% of product revenue at $25.6 billion (17% CER growth), with key drivers including Tagrisso ($7.3 billion, +10% CER), Imfinzi ($6.1 billion, +28% CER), and Enhertu ($2.8 billion AstraZeneca share, +40% CER). Tagrisso dominated first-line EGFRm NSCLC, Imfinzi expanded across lung, GI, and GU indications with new US approvals, and Enhertu accelerated in earlier-line breast cancer and China. These assets, backed by 14 Phase III trials, target mid-teens growth into 2026 and over $10 billion in combined risk-adjusted peak-year revenue.

BioPharma Holds Steady Amid Challenges

BioPharmaceuticals revenue reached $22.0 billion (5% CER growth), with CVRM at $12.8 billion (+2% CER) led by Farxiga ($8.4 billion, +9% CER) in HF and CKD, and R&I at $8.9 billion (+12% CER) featuring Tezspire (+64% CER to $1.1 billion) and Fasenra (+16% CER). CER methodology isolated operational gains, with US (43%) and China (11%) demand supporting R&D at 24% of revenue for trials like CARDIO-TTRansform.

Rare Disease Expands Reach

Rare Disease generated $9.1 billion (+5% CER), highlighted by Ultomiris ($4.7 billion, +19% CER) in PNH and gMG, and Strensiq ($1.7 billion, +18% CER) in HPP. Launches in over 75 countries and upcoming drivers like ICAN in IgAN position it for low double-digit CAGR.

Profitability and Investments Accelerate

Core operating profit hit $18.5 billion (31% margin, +9% CER), with R&D up 12% CER to $13.8 billion funding 100+ Phase III trials, ADCs, and IO bispecifics. Net debt improved to 1.2x EBITDA, with FY 2026 guidance for mid-to-high single-digit revenue growth and low double-digit core EPS growth.

Pipeline Promises $10B+ Opportunities

Over 100 Phase III trials, with 20+ 2026 readouts (>10bn PYR), include camizestrant in ESR1m breast cancer, elecoglipron in obesity/CV, and cliramitug in ATTR-CM. These deepen late-stage assets (37 in Phase III/registration), mitigate LOE risks, and enhance HEOR for market access. The AstraZeneca financial results position the company toward its $80 billion revenue goal by 2030.

Reference url

Recent Posts

Citation Analysis of Real-World Evidence in Medicare Drug Price Negotiations

By João L. Carapinha

March 24, 2026

Medicare Drug Price Negotiations are increasingly relying on real-world evidence, according to a new citation analysis of the first drugs selected under the Inflation Reduction Act. The study examined how the Centers for Medicare and Medicaid Services (CMS) uses real-world evidence (RWE) in its M...
Serplulimab Lung Cancer Treatment: Evaluation of Clinical and Economic Impact in Portugal

By João L. Carapinha

Serplulimab lung cancer treatment has received a positive funding recommendation from Portuguese authorities for first-line use in extensive-stage small cell lung cancer (ES-SCLC), despite not demonstrating added therapeutic value over the current standard. No Added Therapeutic Value...
Cost-Effectiveness of T1D Screening Effectiveness in Canadian Children

By João L. Carapinha

March 23, 2026

T1D screening effectiveness in the general population substantially outperforms targeted approaches based on family history or genetic risk, according to a new Canadian health economic analysis. General population autoantibody screening detects far more at-risk children than family-history or gen...